Answers are grounded in this paper and cite their sources.
Preclinical drug discovery demonstrates reversible DPP1 inhibitor AZD7986 lacks aorta binding liability, indicating potential once-daily treatment for chronic obstructive pulmonary disease.
A novel series of second generation DPP1 inhibitors free from aorta binding liabilities found for earlier compound series was discovered. This work culminated in the identification of compound 30 (AZD7986) as a highly potent, reversible, and selective clinical candidate for COPD, with predicted human PK properties suitable for once daily human dosing.
No takes yet. Share an insight, caveat, or question.
Doyle et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: